Pfizer's bone drug may cause deaths, FDA analysis reports

09/4/2008 | Washington Post, The

Women who got low doses of Pfizer's Fablyn -- a drug candidate for osteoporosis -- were more likely to die within five years compared with those who received placebo, according to an analysis from FDA staff. Reviewers said the once-daily pill is effective for averting fractures in postmenopausal women with osteoporosis, but they are concerned that patients on Fablyn had more than twice the risk of developing blood clots. A panel of independent advisers is scheduled Monday to review the drug's safety.

View Full Article in:

Washington Post, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA